Pentixapharm Holding AG

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
N/A
SEDOL
N/A
CIK
N/A
www.pentixapharm.com
LEI:
©
FIGI: BBG01Q0BTKZ2
PTP
Pentixapharm Holding AG
GICS: - · Sector: - · Sub-Sector: -
AI
PROFILER
NAME
Pentixapharm Holding AG
ISIN
DE000A40AEG0
TICKER
PTP
MIC
XETR
REUTERS
PTP.DE
BLOOMBERG
PTP GR
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Tue, 12.11.2024

Pentixapharm Releases Interim Report for the Third Quarter of 2024 Loss of Pentixapharm Holding AG for the reporting period: €49k No revenue realized during the stub fiscal year through the end of Q3 Current liabilities of €487k, mainly from the purchase of Pentixapharm AG shares Berlin and Würzburg, Germany, November 12, 2024 – Pentixapharm Hol...
Research & Analysis
Read more
Mon, 04.11.2024

Berlin and Würzburg, Germany, November 4, 2024 – Pentixapharm, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, welcomes the recent announcement by the U.S. Centers for Medicare & Medicaid Services (CMS) to implement separate payments for specialized diagnostic radiopharmaceuticals used in the hospital outp...
Research & Analysis
Read more
Tue, 29.10.2024

Berlin and Würzburg, Germany, October 29, 2024 – The National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), two highly respected research organizations belonging to the US government's National Institutes of Health (NIH), have started a clinical trial involving 77 patients to see if Pentixa...
Research & Analysis
Read more
Mon, 28.10.2024

Berlin, Germany, October 28, 2024 – Prof. Dr. Ken Herrmann, a distinguished scientist and Head of the Department of Nuclear Medicine at Universitätsklinikum Essen, Germany, has as of today formally assumed his seat on the Supervisory Board of Pentixapharm Holding AG. While the appointment dates back to the shareholder meeting in June 2024 and has b...
Research & Analysis
Read more
Fri, 25.10.2024

Berlin, Germany, October 25, 2024 - Following the receipt of various approvals, consents, and registrations, Pentixapharm Holding AG will implement, at the end of October 2024, a series of changes to the group's management bodies. As announced, Dr. Hakim Bouterfa, founder and CEO of Pentixapharm AG, will step down from his positions on the Managem...
Research & Analysis
Read more
Sat, 19.10.2024

Hamburg, Germany, October 19, 2024 - The CXCR4 targeting compounds developed clinically by Pentixapharm in a number of diagnostic and therapeutic indications are subject of 17 abstract presentations at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) which takes place in Hamburg from 19 – 23 October 2024. The presenta...
Research & Analysis
Read more
Fri, 18.10.2024

Würzburg and Berlin, Germany, October 18, 2024 - The European Medicine Agency (EMA) has granted PRIME Status to Pentixapharm’s lead candidate Ga68-PentixaFor, thereby granting an early and proactive support for the development of the radiodiagnostic and the possibility of an accelerated approval. The benefits of PRIME status include an early appoin...
Research & Analysis
Read more
Thu, 03.10.2024

ADVERTISEMENT NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL Press Release Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange...
Research & Analysis
Read more
Tue, 01.10.2024

NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL Disclosure of Insider Information according to Article 17 of Regulation (EU) No. 596/2014 Pentixapharm Holding AG: Place...
Research & Analysis
Read more
Mon, 23.09.2024

ADVERTISEMENT NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL Press Release Pentixapharm Holding AG Sets Price Range for Planned IPO Offering of up to 3.9 million new...
Research & Analysis
Read more
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S